- Home
- EOD vs NMRA Comparison
EOD vs NMRA Comparison
Compare EOD & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EOD | NMRA |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.7M | 311.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | EOD | NMRA |
|---|---|---|
| Price | $6.39 | $1.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 105.7K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.48 | $0.83 |
| 52 Week High | $6.74 | $3.65 |
Technical Indicators
Market Signals| Indicator | EOD | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.16 | 42.24 |
| Support Level | $6.29 | $0.83 |
| Resistance Level | $6.53 | $1.72 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 10.34 | 9.09 |
Price Performance
Historical ComparisonAbout EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.